Genomic profiling enables therapy individualization when actionable mutations (FLT3, NPM1, IDH1/2, TP53) are present, moving AML care beyond one-size-fits-all induction and transplant algorithms.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results